James Flinn (@FlinnJP) profile picture

IP Director & Legal Counsel at Immutep

Melbourne, Australia
Joined January 2018
Photo by James Flinn (@FlinnJP)
James Flinn retweeted
The first patient in our TACTI-004 lung cancer trial has been safely dosed in Australia, marking a significant milestone for the team at @Immutep! Read the announcement: bit.ly/4j2hd86 #efti #oncology #clinicaltrial #NSCLC $IMM $IMMP
2
11
770
Sip&Learn Webinar: Immutep's therapies move towards late-stage development @Immutep $IMM $IMMP sharecafe.com.au/2025/02/19/…
2
2
463
James Flinn retweeted
We’re pleased to provide our shareholders with a summary of a busy quarter in Q2 FY25, such as our transition to becoming a #PhaseIII biotech. Read the update: bit.ly/42A1oQI #biotechnology #LAG3 #immunotherapy
1
1
8
423
James Flinn retweeted
ICYMI, catch Marc Voigt’s short presentation at @ausbiztv's Investor Connect event at the end of last year. Marc gives a quick snapshot of how @Immutep's lead product candidate fights cancer and how our late-stage clinical trials are tracking. Watch: bit.ly/3CbPEcn
1
1
7
425
James Flinn retweeted
Marc Voigt, CEO of @Immutep, was delighted to join @ausbiztv's Investor Event to discuss its recent advancements in cancer treatment and its promising outlook following encouraging trial results. Watch the short CEO interview: bit.ly/3PvmYhJ #biotechnology #LAG3
1
1
13
416
James Flinn retweeted
ICYMI: Tune in to replay of fireside chat with Dr. Martin Forster of the @ucl Cancer Institute and @Immutep CEO Marc Voigt for an overview of recent data in 1L HNSCC patients with PD-L1 CPS <1 and insights into TACTI-004 Phase 3 in #lungcancer Replay: bit.ly/4iDg5Z1
1
6
364
Immutep said IMP761 was found safe in initial data from a Phase 1 trial, with no treatment-related adverse events reported. bit.ly/402nf1R #news
1
9
585
James Flinn retweeted
@Immutep is pleased to announce favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating #IMP761. Read more: bit.ly/3DggWPh #biotechnology #AutoimmuneDisease #LAG3 #immunotherapy
1
5
1
16
544
James Flinn retweeted
@Immutep in collab with @RossjohnLab first to publish structure of LAG-3/HLA-II complex & resolve how human LAG-3 binds to its main ligand, providing better foundation for development of blocking #LAG3 therapeutics incl its own small molecule program. bit.ly/3DkXnp2
5
16
544
James Flinn retweeted
@Immutep is proud to report new positive results from efti in combination with KEYTRUDA® at #ESMOIO2024 in first line #HNSCC patients with PD-L1 expression below 1 (CPS <1). Data shows strong overall & progression-free survival and durability. Read more: bit.ly/3Zx0cuz
2
3
1
13
671
Immutep (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. finnewsnetwork.com.au/archiv… $IMM @Immutep
4
6
551
James Flinn retweeted
@Immutep is pleased to share an Investor Update discussing the upcoming TACTI-004 trial & becoming a Phase 3 biotech. The potential for efti combined with KEYTRUDA & chemo is to set a new standard-of-care in #NSCLC Read more here: bit.ly/4eRmFb8 #LungCancerAwarenessMonth
1
2
12
569
Immutep’s LAG-3 Adds To Keytruda In First-Line Lung Cancer ow.ly/8Ey7105OYXA #PharmaScrip
1
2
325